Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 284

1.

Individual therapeutic DAS28-dcrit responses differentiate between effectiveness of rheumatoid arthritis therapies and reflect patient-reported outcomes: retrospective analysis of DAS28 responses in comparative tocilizumab studies.

Koehm M, McIntosh MJ, Hofmann MW, Abraham V, Gabay C, Choy EH, Kavanaugh A, Burkhardt H, Behrens F.

Rheumatol Int. 2020 Feb 10. doi: 10.1007/s00296-020-04514-7. [Epub ahead of print]

PMID:
32040761
2.

Intracellular IL-1 Receptor Antagonist Isoform 1 Released from Keratinocytes upon Cell Death Acts as an Inhibitor for the Alarmin IL-1α.

Martin P, Palmer G, Rodriguez E, Palomo J, Lemeille S, Goldstein J, Gabay C.

J Immunol. 2020 Feb 15;204(4):967-979. doi: 10.4049/jimmunol.1901074. Epub 2020 Jan 13.

PMID:
31932497
3.

Long-term immunogenicity after yellow fever vaccination in immunosuppressed and healthy individuals.

Burkhard J, Ciurea A, Gabay C, Hasler P, Müller R, Niedrig M, Fehr J, Villiger P, Visser LG, de Visser AW, Walker UA, Hatz C, Bühler S.

Vaccine. 2020 Jan 3. pii: S0264-410X(19)31694-9. doi: 10.1016/j.vaccine.2019.12.042. [Epub ahead of print]

PMID:
31911033
4.

Levels of CXCL13 and sICAM-1 correlate with disease activity score in patients with rheumatoid arthritis treated with tocilizumab.

Tuckwell K, Gabay C, Sornasse T, Laubender RP, Wang J, Townsend MJ.

Adv Rheumatol. 2019 Dec 4;59(1):54. doi: 10.1186/s42358-019-0097-1.

PMID:
31801637
5.

Ultrasound is not associated with the presence of systemic autoimmunity or symptoms in individuals at risk for rheumatoid arthritis.

Brulhart L, Alpízar-Rodríguez D, Nissen MS, Zufferey P, Ciubotariu I, Fleury G, Lazarou I, Gabay C, Finckh A.

RMD Open. 2019 Aug 23;5(2):e000922. doi: 10.1136/rmdopen-2019-000922. eCollection 2019.

6.

IL-18 as therapeutic target in a patient with resistant systemic juvenile idiopathic arthritis and recurrent macrophage activation syndrome.

Yasin S, Solomon K, Canna SW, Girard-Guyonvarc'h C, Gabay C, Schiffrin E, Sleight A, Grom AA, Schulert GS.

Rheumatology (Oxford). 2020 Feb 1;59(2):442-445. doi: 10.1093/rheumatology/kez284. No abstract available.

PMID:
31359055
7.

Long-term therapy with anakinra in hidradenitis suppurativa in three patients.

André R, Marescassier H, Gabay C, Pittet B, Laffitte E.

Int J Dermatol. 2019 Nov;58(11):e208-e209. doi: 10.1111/ijd.14596. Epub 2019 Jul 29. No abstract available.

PMID:
31353451
8.

IL-18 as a biomarker linking systemic juvenile idiopathic arthritis and macrophage activation syndrome.

Yasin S, Fall N, Brown RA, Henderlight M, Canna SW, Girard-Guyonvarc'h C, Gabay C, Grom AA, Schulert GS.

Rheumatology (Oxford). 2020 Feb 1;59(2):361-366. doi: 10.1093/rheumatology/kez282.

PMID:
31326996
9.

Comparative effectiveness of TNF inhibitors and tocilizumab with and without conventional synthetic disease-modifying antirheumatic drugs in a pan-European observational cohort of bio-naïve patients with rheumatoid arthritis.

Lauper K, Mongin D, Iannone F, Kristianslund EK, Kvien TK, Nordström DC, Pavelka K, Pombo-Suarez M, Rotar Z, Santos MJ, Codreanu C, Lukina G, Gale SL, John M, Luder Y, Courvoisier DS, Gabay C.

Semin Arthritis Rheum. 2020 Feb;50(1):17-24. doi: 10.1016/j.semarthrit.2019.06.020. Epub 2019 Jun 28.

10.

Drug retention of biological DMARD in rheumatoid arthritis patients: the role of baseline characteristics and disease evolution.

Lauper K, Mongin D, Alpizar-Rodriguez D, Codreanu C, Iannone F, Kristianslund EK, Kvien TK, Pavelka K, Pombo-Suarez M, Santos MJ, Gabay C, Finckh A, Courvoisier DS.

Rheumatology (Oxford). 2019 Dec 1;58(12):2221-2229. doi: 10.1093/rheumatology/kez221.

PMID:
31209481
11.

Inadequate reporting of concomitant medications in rheumatology randomized controlled trials of pharmacologic interventions.

Iudici M, Riveros C, Gabay C, Puéchal X, Berthelot JM, Ravaud P.

Semin Arthritis Rheum. 2019 Dec;49(3):453-458. doi: 10.1016/j.semarthrit.2019.03.009. Epub 2019 Mar 16.

PMID:
30975475
12.

The links of hepcidin and erythropoietin in the interplay of inflammation and iron deficiency in a large observational study of rheumatoid arthritis.

Scholz GA, Leichtle AB, Scherer A, Arndt U, Fiedler M, Aeberli D, Finckh A, Gabay C, Kyburz D, Villiger PM, Möller B.

Br J Haematol. 2019 Jul;186(1):101-112. doi: 10.1111/bjh.15895. Epub 2019 Apr 2.

PMID:
30941747
13.

Safety and immunogenicity of tetanus/diphtheria vaccination in patients with rheumatic diseases-a prospective multi-centre cohort study.

Bühler S, Jaeger VK, Adler S, Bannert B, Brümmerhoff C, Ciurea A, Distler O, Franz J, Gabay C, Hagenbuch N, Herzog C, Hasler P, Kling K, Kyburz D, Müller R, Nissen MJ, Siegrist CA, Villiger PM, Walker UA, Hatz C.

Rheumatology (Oxford). 2019 Sep 1;58(9):1585-1596. doi: 10.1093/rheumatology/kez045.

PMID:
30877773
14.

[Inflammatory arthritides pathotypes].

Lazarou I, Méric De Bellefon L, Lauwerys B, Gabay C.

Rev Med Suisse. 2019 Mar 6;15(641):522-527. French.

PMID:
30860321
15.

Polyarthrite rhumatoïde : ce qui a changé et ce qu’il reste encore à faire.

Gabay C, Hügle T.

Rev Med Suisse. 2019 Mar 6;15(641):519-520. French. No abstract available.

PMID:
30860320
16.

Prevotella copri in individuals at risk for rheumatoid arthritis.

Alpizar-Rodriguez D, Lesker TR, Gronow A, Gilbert B, Raemy E, Lamacchia C, Gabay C, Finckh A, Strowig T.

Ann Rheum Dis. 2019 May;78(5):590-593. doi: 10.1136/annrheumdis-2018-214514. Epub 2019 Feb 13.

PMID:
30760471
17.

Response to: 'When binary and continuous responses disagree' by Dr Ouyang.

Lauper K, Courvoisier DS, Gabay C.

Ann Rheum Dis. 2019 Jan 30. pii: annrheumdis-2019-215019. doi: 10.1136/annrheumdis-2019-215019. [Epub ahead of print] No abstract available.

PMID:
30700423
18.

Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries.

Lauper K, Mongin D, Iannone F, Klami Kristianslund E, Kvien TK, Nordström D, Pavelka K, Pombo-Suarez M, Rotar Z, Santos MJ, Codreanu C, Lukina G, Courvoisier DS, Gabay C.

RMD Open. 2018 Nov 5;4(2):e000809. doi: 10.1136/rmdopen-2018-000809. eCollection 2018. Erratum in: RMD Open. 2019 Dec 23;5(2):e000809corr1.

19.

Role of reproductive and menopausal factors in functional and structural progression of rheumatoid arthritis: results from the SCQM cohort.

Alpizar-Rodriguez D, Förger F, Courvoisier DS, Gabay C, Finckh A.

Rheumatology (Oxford). 2019 Mar 1;58(3):432-440. doi: 10.1093/rheumatology/key311.

PMID:
30380120
20.

Prolonged treatment with Tadekinig alfa in adult-onset Still's disease.

Kiltz U, Kiefer D, Braun J, Schiffrin EJ, Girard-Guyonvarc'h C, Gabay C.

Ann Rheum Dis. 2020 Jan;79(1):e10. doi: 10.1136/annrheumdis-2018-214496. Epub 2018 Oct 23. No abstract available.

PMID:
30352887
21.

Smoking and response to rituximab in rheumatoid arthritis: results from an international European collaboration.

Chatzidionysiou K, Lukina G, Gabay C, Hetland ML, Hauge EM, Pavelka K, Nordström D, Canhão H, Tomsic M, Rotar Z, Lie E, Kvien TK, van Vollenhoven RF, Saevarsdottir S.

Scand J Rheumatol. 2019 Jan;48(1):17-23. doi: 10.1080/03009742.2018.1466363. Epub 2018 Sep 27.

PMID:
30260261
22.

Comparison of Serological Biomarkers in Rheumatoid Arthritis and Their Combination to Improve Diagnostic Performance.

Martinez-Prat L, Nissen MJ, Lamacchia C, Bentow C, Cesana L, Roux-Lombard P, Gabay C, Mahler M.

Front Immunol. 2018 Jun 6;9:1113. doi: 10.3389/fimmu.2018.01113. eCollection 2018.

23.

Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration.

Lauper K, Nordström DC, Pavelka K, Hernández MV, Kvien TK, Kristianslund EK, Santos MJ, Rotar Ž, Iannone F, Codreanu C, Lukina G, Gale SL, Sarsour K, Luder Y, Courvoisier DS, Gabay C.

Ann Rheum Dis. 2018 Sep;77(9):1276-1282. doi: 10.1136/annrheumdis-2017-212845. Epub 2018 May 5.

PMID:
29730637
24.

Biological agents in the management of adult-onset Still's disease.

Girard-Guyonvarc'h C, Gabay C.

Joint Bone Spine. 2019 Jan;86(1):5-7. doi: 10.1016/j.jbspin.2018.03.010. Epub 2018 Apr 6. No abstract available.

PMID:
29631071
25.

Incidence and Prevalence of Major Adverse Cardiovascular Events in Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis.

Lauper K, Courvoisier DS, Chevallier P, Finckh A, Gabay C.

Arthritis Care Res (Hoboken). 2018 Dec;70(12):1756-1763. doi: 10.1002/acr.23567.

26.

Identification of sarilumab pharmacodynamic and predictive markers in patients with inadequate response to TNF inhibition: a biomarker substudy of the phase 3 TARGET study.

Gabay C, Msihid J, Zilberstein M, Paccard C, Lin Y, Graham NMH, Boyapati A.

RMD Open. 2018 Mar 14;4(1):e000607. doi: 10.1136/rmdopen-2017-000607. eCollection 2018.

27.

[Management of septic arthritis].

Debrach AC, Lazarou I, Gabay C, Uçkay I.

Rev Med Suisse. 2018 Mar 7;14(597):516-521. French.

PMID:
29512948
28.

L’homme et les microbes : les deux faces d’une même médaille.

Hügle T, Gabay C.

Rev Med Suisse. 2018 Mar 7;14(597):507. French. No abstract available.

PMID:
29512946
29.

Variable domain N-linked glycosylation and negative surface charge are key features of monoclonal ACPA: Implications for B-cell selection.

Lloyd KA, Steen J, Amara K, Titcombe PJ, Israelsson L, Lundström SL, Zhou D, Zubarev RA, Reed E, Piccoli L, Gabay C, Lanzavecchia A, Baeten D, Lundberg K, Mueller DL, Klareskog L, Malmström V, Grönwall C.

Eur J Immunol. 2018 Jun;48(6):1030-1045. doi: 10.1002/eji.201747446. Epub 2018 Apr 6.

30.

Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease.

Gabay C, Fautrel B, Rech J, Spertini F, Feist E, Kötter I, Hachulla E, Morel J, Schaeverbeke T, Hamidou MA, Martin T, Hellmich B, Lamprecht P, Schulze-Koops H, Courvoisier DS, Sleight A, Schiffrin EJ.

Ann Rheum Dis. 2018 Jun;77(6):840-847. doi: 10.1136/annrheumdis-2017-212608. Epub 2018 Feb 22.

31.

β Cell-Specific Deletion of the IL-1 Receptor Antagonist Impairs β Cell Proliferation and Insulin Secretion.

Böni-Schnetzler M, Häuselmann SP, Dalmas E, Meier DT, Thienel C, Traub S, Schulze F, Steiger L, Dror E, Martin P, Herrera PL, Gabay C, Donath MY.

Cell Rep. 2018 Feb 13;22(7):1774-1786. doi: 10.1016/j.celrep.2018.01.063.

32.

Nanocrystal-Polymer Particles: Extended Delivery Carriers for Osteoarthritis Treatment.

Maudens P, Seemayer CA, Thauvin C, Gabay C, Jordan O, Allémann E.

Small. 2018 Feb;14(8). doi: 10.1002/smll.201703108. Epub 2018 Jan 12.

PMID:
29327460
33.

Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome.

Weiss ES, Girard-Guyonvarc'h C, Holzinger D, de Jesus AA, Tariq Z, Picarsic J, Schiffrin EJ, Foell D, Grom AA, Ammann S, Ehl S, Hoshino T, Goldbach-Mansky R, Gabay C, Canna SW.

Blood. 2018 Mar 29;131(13):1442-1455. doi: 10.1182/blood-2017-12-820852. Epub 2018 Jan 11.

34.

Unopposed IL-18 signaling leads to severe TLR9-induced macrophage activation syndrome in mice.

Girard-Guyonvarc'h C, Palomo J, Martin P, Rodriguez E, Troccaz S, Palmer G, Gabay C.

Blood. 2018 Mar 29;131(13):1430-1441. doi: 10.1182/blood-2017-06-789552. Epub 2018 Jan 2.

PMID:
29295842
35.

Inflammasome Adaptor ASC Suppresses Apoptosis of Gastric Cancer Cells by an IL18-Mediated Inflammation-Independent Mechanism.

Deswaerte V, Nguyen P, West A, Browning AF, Yu L, Ruwanpura SM, Balic J, Livis T, Girard C, Preaudet A, Oshima H, Fung KY, Tye H, Najdovska M, Ernst M, Oshima M, Gabay C, Putoczki T, Jenkins BJ.

Cancer Res. 2018 Mar 1;78(5):1293-1307. doi: 10.1158/0008-5472.CAN-17-1887. Epub 2017 Dec 27.

36.

Regulation and function of interleukin-36 cytokines.

Bassoy EY, Towne JE, Gabay C.

Immunol Rev. 2018 Jan;281(1):169-178. doi: 10.1111/imr.12610. Review.

PMID:
29247994
37.

The perioperative use of synthetic and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.

Fleury G, Mania S, Hannouche D, Gabay C.

Swiss Med Wkly. 2017 Dec 11;147:w14563. doi: 10.4414/smw.2017.14563. eCollection 2017. Review.

38.

Salt-inducible kinases (SIK) inhibition reduces RANKL-induced osteoclastogenesis.

Lombardi MS, Gilliéron C, Berkelaar M, Gabay C.

PLoS One. 2017 Oct 3;12(10):e0185426. doi: 10.1371/journal.pone.0185426. eCollection 2017.

39.

Impact of tocilizumab monotherapy on patient-reported outcomes in patients with rheumatoid arthritis from two randomised controlled trials.

Strand V, Michalska M, Birchwood C, Pei J, Tuckwell K, Finch R, Gabay C, Kavanaugh A, Jones G.

RMD Open. 2017 Sep 14;3(2):e000496. doi: 10.1136/rmdopen-2017-000496. eCollection 2017.

40.

Treatment efficacy and methotrexate-related toxicity in patients with rheumatoid arthritis receiving methotrexate in combination with adalimumab.

Burmester GR, Kaeley GS, Kavanaugh AF, Gabay C, MacCarter DK, Nash P, Takeuchi T, Goss SL, Rodila R, Chen K, Kupper H, Kalabic J.

RMD Open. 2017 Sep 17;3(2):e000465. doi: 10.1136/rmdopen-2017-000465. eCollection 2017.

41.

Female hormonal factors and the development of anti-citrullinated protein antibodies in women at risk of rheumatoid arthritis.

Alpizar-Rodriguez D, Mueller RB, Möller B, Dudler J, Ciurea A, Zufferey P, Kyburz D, Walker UA, von Mühlenen I, Roux-Lombard P, Mahler M, Lamacchia C, Courvoisier DS, Gabay C, Finckh A.

Rheumatology (Oxford). 2017 Sep 1;56(9):1579-1585. doi: 10.1093/rheumatology/kex239.

PMID:
28859327
42.

[Adverse events of biologic therapies].

Fleury G, Gabay C.

Rev Med Suisse. 2017 Mar 8;13(553):542-548. Review. French.

PMID:
28718586
43.

Complications iatrogènes : ce que tout médecin doit connaître.

Gabay C, So A.

Rev Med Suisse. 2017 Mar 8;13(553):539-540. French. No abstract available.

PMID:
28718585
44.

Rheumatoid arthritis: from basic findings and clinical manifestations to future therapies.

Hasler P, Gabay C.

Semin Immunopathol. 2017 Jun;39(4):339-341. doi: 10.1007/s00281-017-0635-z. Epub 2017 Jun 21. No abstract available.

PMID:
28639062
45.

Reply.

Canna SW, Girard C, Malle L, de Jesus A, Romberg N, Kelsen J, Surrey LF, Russo P, Sleight A, Schiffrin E, Gabay C, Goldbach-Mansky R, Behrens EM.

J Allergy Clin Immunol. 2017 Jul;140(1):316-317. doi: 10.1016/j.jaci.2017.03.016. Epub 2017 Apr 29. No abstract available.

PMID:
28460789
46.

Cardiovascular risk in patients with rheumatoid arthritis.

Lauper K, Gabay C.

Semin Immunopathol. 2017 Jun;39(4):447-459. doi: 10.1007/s00281-017-0632-2. Epub 2017 Apr 28. Review.

PMID:
28455580
47.

International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus.

Kleinmann JF, Tubach F, Le Guern V, Mathian A, Richez C, Saadoun D, Sacre K, Sellam J, Seror R, Amoura Z, Andres E, Audia S, Bader-Meunier B, Blaison G, Bonnotte B, Cacoub P, Caillard S, Chiche L, Chosidow O, Costedoat-Chalumeau N, Daien C, Daugas E, Derdèche N, Doria A, Fain O, Fakhouri F, Farge D, Gabay C, Guillo S, Hachulla E, Hajjaj-Hassouni N, Hamidou M, Houssiau FA, Jourde-Chiche N, Koné-Paut I, Ladjouz-Rezig A, Lambotte O, Lipsker D, Mariette X, Martin-Silva N, Martin T, Maurier F, Meckenstock R, Mékinian A, Meyer O, Mohamed S, Morel J, Moulin B, Mulleman D, Papo T, Poindron V, Puéchal X, Punzi L, Quartier P, Sailler L, Smail A, Soubrier M, Sparsa A, Tazi-Mezalek Z, Zakraoui L, Zuily S, Sibilia J, Gottenberg JE.

Autoimmun Rev. 2017 Jun;16(6):650-657. doi: 10.1016/j.autrev.2017.04.011. Epub 2017 Apr 18.

PMID:
28434948
48.

Presence of IL-17 in synovial fluid identifies a potential inflammatory osteoarthritic phenotype.

Snelling SJ, Bas S, Puskas GJ, Dakin SG, Suva D, Finckh A, Gabay C, Hoffmeyer P, Carr AJ, Lübbeke A.

PLoS One. 2017 Apr 11;12(4):e0175109. doi: 10.1371/journal.pone.0175109. eCollection 2017.

49.

IL-38 overexpression induces anti-inflammatory effects in mice arthritis models and in human macrophages in vitro.

Boutet MA, Najm A, Bart G, Brion R, Touchais S, Trichet V, Layrolle P, Gabay C, Palmer G, Blanchard F, Le Goff B.

Ann Rheum Dis. 2017 Jul;76(7):1304-1312. doi: 10.1136/annrheumdis-2016-210630. Epub 2017 Mar 13.

PMID:
28288964
50.

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.

Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van Vollenhoven R, Aletaha D, Aringer M, Boers M, Buckley CD, Buttgereit F, Bykerk V, Cardiel M, Combe B, Cutolo M, van Eijk-Hustings Y, Emery P, Finckh A, Gabay C, Gomez-Reino J, Gossec L, Gottenberg JE, Hazes JMW, Huizinga T, Jani M, Karateev D, Kouloumas M, Kvien T, Li Z, Mariette X, McInnes I, Mysler E, Nash P, Pavelka K, Poór G, Richez C, van Riel P, Rubbert-Roth A, Saag K, da Silva J, Stamm T, Takeuchi T, Westhovens R, de Wit M, van der Heijde D.

Ann Rheum Dis. 2017 Jun;76(6):960-977. doi: 10.1136/annrheumdis-2016-210715. Epub 2017 Mar 6. Review.

Supplemental Content

Support Center